Amarin reports Q1 EPS (2) vs (1c) last year

Reports Q1 revenue $41M vs $55M last year. “As we begin 2025, our first quarter operational and financial performance reflects continued steady execution against our strategy to maximize the global value of VASCEPA(R)/VAZKEPA(R) while managing external pressures and exercising prudent financial management to maintain a strong capital structure,” said Aaron Berg, President & CEO, Amarin (AMRN). “Our first quarter update underscores continued progress from our strategic initiatives to enhance revenue streams and drive value for our shareholders and patients alike. Looking ahead, our focus remains clear: capitalize on the significant opportunity in Europe, efficiently generate revenue and strong cash flow in the U.S. and Rest of World markets and tightly manage operating expenses to support our strong balance sheet. Underpinning this work is our disciplined evaluation of opportunities to expand the impact and untapped potential of VASCEPA/VAZKEPA to tackle the growing challenge of cardiovascular risk worldwide. That is our continued commitment to all Amarin stakeholders.”